 | SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 949:295-303 (2001)
© 2001 New York Academy of Sciences
Raloxifene: Risks and Benefits
ELIZABETH BARRETT-CONNOR
Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, California 92093, USA
Address for correspondence: Elizabeth Barrett-Connor, M.D., Professor of Family and Preventive Medicine, Chief, Division of Epidemiology, 9500 Gilman Drive #0607, University of California, San Diego, La Jolla, CA 92093.
ebarrettconnor{at}ucsd.edu
Raloxifene, a selective estrogen receptor modulator (SERM), was designed to have the expected benefits of long-term estrogen replacement therapy without the risks. This paper reviews the clinical trial evidence for raloxifene benefits and risks, and how they compare with those of hormone replacement therapy (HRT) and relate to the choices of postmenopausal women.
Key Words: selective estrogen receptor modulators (SERMs) • raloxifene • risks • benefits
This article has been cited by other articles:
|
|
|
|
 
B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol.,
January 10, 2005;
23(2):
357 - 367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Nilsson, J. Falk, E. M. Ritzen, J. Baron, and L. Savendahl
Raloxifene Acts as an Estrogen Agonist on the Rabbit Growth Plate
Endocrinology,
April 1, 2003;
144(4):
1481 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
